| Literature DB >> 26071993 |
Philippe Castellant1, Romain Didier1, Eric Bezon1, Francis Couturaud1, Hélène Eltchaninoff2, Bernard Iung3, Patrick Donzeau-Gouge4, Karine Chevreul5, Jean Fajadet6, Pascal Leprince6, Alain Leguerrier7, Michel Lievre8, Alain Prat9, Emmanuel Teiger5, Marc Laskar10, Jacques Boschat1, Martine Gilard11.
Abstract
Previous coronary artery bypass grafting (CABG) increases operative risk in conventional valve replacement. Transcatheter aortic valve implantation (TAVI) has been shown to be successful in high-risk patient subgroups. The present study compared outcome and overall survival in patients who underwent TAVI with and without history of CABG. From January 2010 to December 2011, 683 of the 3,761 patients selected for TAVI in 34 French centers (18%) had a history of CABG. Outcomes (mortality and complications) were collected prospectively according to the Valve Academic Research Consortium (VARC) criteria. Patients with previous CABG were younger, with higher rates of diabetes and vascular disease and higher logistic European System for Cardiac Operative Risk Evaluation (29.8 ± 16.4 vs 20.1 ± 13.0, p <0.001) but lower rates of pulmonary disease. Two types of valve (Edwards SAPIEN and Medtronic CoreValve) were implanted in equal proportions in the 2 groups. The 30-day and 1-year mortality rates from all causes on Kaplan-Meier analysis (9.2% vs 9.7%, p = 0.71; and 19.0% vs 20.2%, p = 0.49, respectively) did not differ according to the history of CABG. There were no significant differences in the Valve Academic Research Consortium complications (myocardial infarction, stroke or vascular, and bleeding complications). On multivariate analysis, CABG was not associated with greater 1-year post-TAVI mortality. In conclusion, previous CABG did not adversely affect outcome in patients who underwent TAVI, which may be an alternative to surgery in high-risk patients with severe aortic stenosis and history of CABG.Entities:
Mesh:
Year: 2015 PMID: 26071993 DOI: 10.1016/j.amjcard.2015.04.057
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778